Financial Results 9M 2026

In the first nine months of 2026, we continued to deliver solid results, driven by strong commercial and operational execution and the continued growth of our European Dermatology business.

Total Net Sales increased by 8.3% year-on-year to €889.2 million, while EBITDA grew by 22.7% to €221.7 million, reaching a 24.9% margin. European Dermatology remained the main growth driver, with Net Sales increasing by 17.6% year-on-year to €520.3 million, supported by the continued performance of key growth drivers.

Innovation also remains central to our growth strategy and ambition to lead in medical dermatology. Our R&D efforts are rooted in a deep scientific understanding of skin diseases, with the aim of turning research into meaningful new solutions that address the needs of patients and dermatologists.

Building on this strong performance and our position in medical dermatology, we reiterate our full-year 2026 guidance.

Discover more about our 9M 2026 performance in the video with Carlos Gallardo, Chairman & CEO, and Jon U Garay Alonso, Chief Financial Officer.